缺血性卒中占整个卒中的70％以上,是临床上常见的急症,但其治疗尚存在许多困难。虽然临床证据表明重组组织型纤溶酶原激活剂(rt-PA)作为治疗缺血性卒中最有效的药物已有10年历史,已经被美国、加拿大和大部分欧洲国家认可,但在中国的临床实践应用中,rt-PA的使用仍存在诸多问题,集中表现在应用比例极低且使用不规范等。为了促进rt—PA临床治疗的接受程度及规范使用,中华内科杂志编辑部组织部分神经科专家对有关rt-PA溶栓治疗的研究进行了回顾并达成共识。 Ischemic stroke accounts for more than 70% of the total stroke, which is a common clinical emergency, but its treatment still has many difficulties. Although clinical evidence suggests that recombinant tissue plasminogen activator (rt-PA) has been approved as the most effective drug in ischemic stroke for 10 years and has been approved by the United States, Canada and most European countries, In clinical practice, the use of rt-PA still has many problems, which are mainly manifested in the extremely low application rate and the non-standard use. In order to promote the acceptance of rt-PA clinical treatment and regulate the use of the Department of Internal Medicine, Department of Neurology, editorial department of neurology experts on the rt-PA thrombolytic therapy were reviewed and reached a consensus.